Eikon Presents ESMO Data Across Three Programs, Including First Clinical Results for EIK1004 and EIK1005
EIKN sits 28% above its 52-week low of $6.448.
Summary
Eikon disclosed first clinical data for EIK1004 and EIK1005 alongside updated EIK1003 cohorts at ESMO 2026, broadening its pipeline story but with the next readouts not expected until 2027.
Key Events · Product Development and Regulatory · EIKN
-
First EIK1004 and EIK1005 Data
EIK1004, the CNS-penetrant PARP1 inhibitor, showed no dose-limiting toxicities in 68 patients, with Grade 3+ anemia and neutropenia at 1.5% (1/68) each and ORR of 12.1% (7/58). EIK1005, the WRN helicase inhibitor, cleared 50-200 mg weekly with no DLTs, and 6 of 8 evaluable patients (75%) achieved stable disease.
-
EIK1003 Response Concentrated in PARP-Naive
Monotherapy ORR was 14.3% (7/49) overall but 31.3% (5/16) in PARP-naive patients versus 6.1% (2/33) in those previously treated with a PARP inhibitor. The weekly paclitaxel combination cohort posted ORR of 26.4% (14/53) and DCR of 79.2% (42/53).
-
Prostate Combo Shows Early Activity
EIK1003 plus abiraterone in metastatic prostate cancer produced ORR of 20.8% (5/24), DCR of 83.3% (20/24) and PSA50 response in 30.8% (12/39) of PSA-evaluable patients.
-
Next Readouts Pushed to 2027
Initial Cohort 1D (EIK1003 with paclitaxel and platinum) and Phase 2 dose optimization results are expected in the second half of 2027; EIK1005 pembrolizumab combination data in the first half of 2027 and full monotherapy results in the second half of 2027.
Analysis · EIKN · Life Sciences
Eikon has now put its first clinical numbers on two of its three pipeline assets. EIK1004, the CNS-penetrant PARP1 inhibitor, showed minimal bone-marrow suppression (Grade 3+ anemia and neutropenia at 1.5% each) with a 12.1% response rate. EIK1005, the internally discovered WRN helicase inhibitor, cleared three weekly dose levels with no dose-limiting toxicities and produced stable disease in 6 of 8 evaluable patients, all with MSI-H/dMMR tumors. The updated EIK1003 data sharpen the picture further: responses concentrate in PARP-naive patients (31.3% vs 6.1% previously treated), which frames the eventual commercial positioning. For a clinical-stage company that reported a $171.4 million net loss and $531.2 million of cash in its Q2 10-Q, a broader, de-risked pipeline is what supports the next financing and partnership conversations. Timing is the trade-off: the next meaningful readouts (Cohort 1D, the EIK1004 docetaxel arm, full EIK1005 monotherapy data) are all guided to 2027, so there is no near-term catalyst in these results.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.5% of the 1575 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EIKN was trading at $8.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $446.3M. The 52-week trading range was $6.45 to $17.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.